“We are not in a consensus, but we are in a convergence”

Before the Longevity Show, Steve Horvath explains why accurate measurement is the first step in the preventive health revolution.

In Longevity show returns with a program that reflects a field in transition—no longer content with abstract promises of life extension, but more focused on the practicalities of delivery, measurement, and clinical integration. The second day Business conferenceframed around Engagement with a long-term futurebuilding on this transition, it brings together clinicians, scientists, and operators to explore how new tools and technologies translate into real-world health optimization. This is a subtle but important calibration; away from theory and into practice, where questions of evidence, scalability and standardization weigh more heavily than ambition.

Between sessions, The science of evaluation puts measurement at the heart of the longevity conversation—a topic that has been gaining traction with enthusiasm. Featuring Altos Labs Principal Investigator Dr. Steve Horvath, along with Phil Newman, Dr. Raghib Ali, and Dr. Samantha Decombel, the discussion will focus on biomarkers, multiomics, and evidence-based testing as a foundation for personalized, long-term care. Horvath’s presence is especially noteworthy; as the architect of the epigenetic clock, his work did more than anything else to move biological age from an abstraction to a quantitative metric, creating both the opportunity and the degree of scrutiny required.

Longevity.Technology: If longevity medicine is to resemble anything resembling a clinical discipline beyond well-targeted optimization, it must answer a deceptively simple question: how do we measure it? Sessions like this show that the industry is taking this challenge seriously—not through a single biomarker or platform, but through a layered approach that combines molecular data, long-term follow-up, and increasingly sophisticated interpretation. Horvath’s contribution is at the heart of this evolution; his epigenetic clock has become both a tool and a loaded device, forcing the sector with what it shows what biological age is and how much it can be done with confidence. Around this, a wider ecosystem emerges – multi-faceted dashboards, AI analytics, clinical protocols – each promising clarity, each introducing its own complexity. Perhaps the danger is that measurement is more than meaningful, and data accumulates faster than consensus. However, without such efforts, longevity remains descriptive rather than actionable. In this sense, the real importance of sessions like this is not in a single understanding, but in trying to build a coherent diagnostic framework – an ability to translate biological signals into decisions, interventions and, finally, results that can be tracked over time. Ahead of the longevity show, we sat down with Dr. Steve Horvath to discuss the biological reality of epigenetic timing and the need for clinical uniformity..

More riding than the first wave

For all the proliferation of biological age clocks — and the inevitable confusion that has followed — Horvath is clear that the field isn’t all that fragmented. “We’re not in consensus, but we’re in convergence,” he said, referring to gradual harmonization around a smaller number of approved tools.

The first generation of clocks taught against chronological age served a purpose but were never designed with clinical interpretation in mind. “The first wave of watches was trained against chronological age, which is useful for certain applications but limited in human clinical trials,” he said. More recent iterations, including PhenoAge and GrimAge, are based on phenotypic outcomes and mortality, while DunedinPACE attempts to quantify the rate at which a person ages.

This evolution is beginning to crystallize into something more structured. Horvath describes an emerging set of criteria that any clinically relevant biomarker must meet: “it must predict difficult outcomes, such as time to death or specific diseases, it must move in response to interventions, and it must be reproducible in the population.” The direction of the journey is encouraging, even if the destination is out of reach. “We’re much closer to that level than we were five years ago, but the alignment of analytics and potentially interventional data is still a work in progress. Almost there.”

A moment of harmony

If the science is converging, so is the wider ecosystem around it – which, in Horvath’s view, explains why events like The Longevity Show are emerging with a more practical and translational focus.

“A few things fit together,” he says. “The herology hypothesis, that targeting the biology of aging is a viable strategy, is no longer valid.” This shift has been accompanied by significant advances: endpoints that obviate the need for decades-long studies of mortality, early human trials reporting results, and an increasing influx of capital from both established players and newer longevity-focused ventures.

Then there are the demographics – impossible to ignore and increasingly difficult to delay. “Aging populations in most developed countries,” notes Horvath, have turned longevity from an intellectual curiosity to something closer to a political and economic imperative. “Promoting or reversing aging has probably become an economic and medical priority rather than a curiosity.”

However, he offers a note of caution – or perhaps realism. “The weight of honest resistance is that there’s a lot of wishful thinking compared to hard data,” he says, adding that he hopes forums like this one can “help separate the signal from the hype.”

Exact limits

As measurement becomes more complex, it also becomes more nuanced and in some ways more complex. The idea of ​​an accurate reading of biological age remains attractive, but Horvath is quick to question the premise.

“I think the premise needs to be corrected first: we still cannot measure biological age with perfect accuracy,” he said. No, he suggests, this is never possible through a single metric. “Biological age is multifaceted. The full picture comes from a basket of measurements.”

This basket is wide; blood biochemical panels, methylation data, proteomics and metabolomics sit alongside images, wearable data and functional assessments such as VO2 max, muscle strength and cognitive function. Each involves a different aspect of the biology of aging, and none can stand completely alone.

The question of how people deal with this information is the same. For some, the act of measuring is inherently motivating. “Some people really enjoy measuring. I’m one of them,” admits Horvath. “I treat it as a hobby and it makes me follow a healthy lifestyle.” However, others may find the same information overwhelming or disturbing. “Too much scrutiny worries them. I respect that.”

His advice, characteristically, comes up somewhere. “There’s a reasonable middle ground. Get your blood pressure and vitals checked about once a year. Pay attention to the basics. But if you’re not a lifelong athlete, don’t be tempted.” A deeper point, however, is less technical and more human. “Your happiness and purpose isn’t built on test scores. It’s built on friendships, purpose, making time for fun, good sleep, and movement. Tests are a helpful nudge, at least for me, but they’re not a destination.”

More than an hour

For someone whose work helped define the industry, Horvath is especially excited about what’s to come. The concept of a single whole-body watch may eventually evolve into something much more polished.

“The most important (frontier) is moving from whole-body, blood-based clocks to clocks that accurately measure the biological age of individual organs and organ systems,” he says, pointing to the brain, kidney, lung, liver and heart as obvious candidates. Such determination allows physicians to identify which systems within an individual are aging most rapidly—and to intervene before dysfunction becomes clinically apparent.

This, in turn, raises a more fundamental question. “Can we find targeted interventions that reverse the damage or rejuvenate the organ before it fails?” If the answer is yes, the implications go beyond individual health. “We’re changing the entire economics of medicine because prevention is significantly cheaper than treatment. One stitch in time saves nine nines.”

For researchers, the horizon stretches even further toward more and more accurate models of aging. Horvath points to “single-cell aging clocks in different species” as another emerging field—noting that even as the field moves closer to clinical application, its scientific underpinnings continue to evolve.